µ¿¹ÝÁø´Ü ½ÃÀå : Á¦Ç° À¯Çüº°, ¿ëµµº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Companion Diagnostics Market, By Product Type, By Application, By Technology, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1477175
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 260 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,539,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,495,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,892,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

µ¿¹ÝÁø´Ü ½ÃÀå ±Ô¸ð´Â 2023³â 69¾ï 7,812¸¸ ´Þ·¯·Î 2024³âºÎÅÍ 2032³â±îÁö CAGR 12.2%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

µ¿¹ÝÁø´Ü ½ÃÀå : ½ÃÀå ¿ªÇÐ

°³º°È­ ÀÇ·áÀÇ Á߿伺 Áõ´ë

°³°³ÀÎÀÇ À¯ÀüÀû ±¸¼º°ú Ư¼º¿¡ ¸Â´Â Ä¡·á°¡ °¡´ÉÇØÁü¿¡ µû¶ó °³ÀÎ ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. µ¿¹ÝÁø´ÜÀº ȯÀÚ°¡ ƯÁ¤ Ä¡·á¿¡ ¾î¶»°Ô ¹ÝÀÀÇÒÁö ¿¹ÃøÇÒ ¼ö ÀÖ´Â ¹ÙÀÌ¿À¸¶Ä¿¿Í À¯ÀüÀÚ º¯À̸¦ ½Äº°ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. À̸¦ ÅëÇØ ÀÇ»ç´Â ȯÀÚº° À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î °¢ ȯÀÚ¿¡°Ô °¡Àå ÀûÇÕÇÑ ¾à¹°À» ó¹æÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °Ë»ç¸¦ ÅëÇØ ÀÇ·áÁøÀº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÓ»óÀû ÆÇ´ÜÀ» ³»¸± ¼ö ÀÖ°í, ºÒÇÊ¿äÇÑ ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÇÇÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ °³ÀθÂÃãÇü ÀǾàǰ°ú µ¿¹ÝÁø´ÜÀÇ Á߿伺ÀÌ ³ô¾ÆÁü¿¡ µû¶ó, º¸´Ù Á¤È®Çϰí È¿°úÀûÀΠȯÀÚ Áß½ÉÀÇ Ä¡·á Á¢±Ù¹ýÀ¸·ÎÀÇ ÆÐ·¯´ÙÀÓ ÀüȯÀÌ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.

µ¿¹ÝÁø´Ü ½ÃÀå : ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¿¬±¸ ºÐ¼®°¡µéÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¿¬Æò±Õ ¾à 12.2%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â ºÐ¼®, ŰƮ ¹× ½Ã¾à ºÐ¾ß°¡ ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ß°¡ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ÀÌ ºÐ¾ß°¡ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¸ÅÃâÀ» ÁÖµµÇß½À´Ï´Ù.

µ¿¹ÝÁø´Ü ½ÃÀå : ¼¼ºÐÈ­ ºÐ¼®:

¼¼°è µ¿¹ÝÁø´Ü ½ÃÀåÀº Á¦Ç° À¯Çü, ±â¼ú, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

Á¦Ç° À¯Çü¿¡ µû¶ó ºÐ¼®, ŰƮ ¹× ½Ã¾à, ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º µÎ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ºÐ¼®, ŰƮ ¹× ½Ã¾à ºÐ¾ß´Â ´Ù¾çÇÑ Á¦Ç° °¡¿ë¼º, ºÐ¼® ¹× ÇコÄÉ¾î ºÐ¾ß¿¡¼­ÀÇ »ç¿ë È®´ë µîÀ¸·Î ÀÎÇØ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾»ç¿ëÀÚ¿¡ µû¶ó Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷, ÀÓ»ó ¿¬±¸ ±â°ü, ÂüÁ¶ ½ÇÇè½Ç µî ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. Á¦¾à ¹× »ý¸í°øÇÐ ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ±× ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. µ¿¹ÝÁø´ÜÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ´Â ¹è°æ¿¡´Â ÇコÄÉ¾î »ê¾÷¿¡¼­ ÀǾàǰ °³¹ßÀÇ Á߿伺ÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.

µ¿¹ÝÁø´Ü ½ÃÀå : Áö¸®Àû ÀλçÀÌÆ®

Áö¸®ÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ºñÁî´Ï½º¸¦ °¡Á®¿À´Â ±¹°¡¿¡ µû¶ó ´õ ¼¼ºÐÈ­µË´Ï´Ù.

µ¿¹ÝÁø´Ü ½ÃÀåÀº ºÏ¹Ì°¡ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ´Ù¼öÀÇ À¯¸í µ¿¹ÝÁø´Ü º¥´õ¿Í °³¹æÇü Àӻ󿬱¸½Ã¼³ÀÇ Á¸Àç, ±â¼úÀûÀ¸·Î Áøº¸µÈ ±â±â ¹× µµ±¸ÀÇ ½¬¿î Á¢±Ù¼º, ¹Ì±¹ ¹× ij³ª´ÙÀÇ ÀÇ·á ¼­ºñ½º ÀÎÇÁ¶ó°¡ Å©°Ô º¯È­Çϰí ÀÖ´Â Á¡ µîÀÌ ºÏ¹Ì µ¿¹ÝÁø´Ü ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾çÀº Àα¸°¡ ¸¹°í, µ¿¹ÝÁø´Ü¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í, ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖÀ¸¸ç, ÷´Ü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ÁøÀÔ ±â¾÷¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 11¿ù FDA´Â FoundationOne CDx¸¦ È£¸£¸ó ¼ö¿ëü ¾ç¼º ÁøÇ༺ À¯¹æ¾Ï ȯÀÚ¸¦ ½Äº°ÇÏ´Â º¸Á¶ Áø´ÜÀ¸·Î »ç¿ëÇϵµ·Ï ½ÂÀÎÇß½À´Ï´Ù.

µ¿¹ÝÁø´Ü ½ÃÀå : °æÀï »óȲ:

°­·ÂÇÑ ±¹Á¦Àû ÀÔÁö¿Í ÆÇ¸Å¸ÁÀ» °®Ãá ±â¾÷Àº Àü ¼¼°è ÀÇ·áÁø°ú ȯÀڵ鿡°Ô Á¢±ÙÇÏ´Â µ¥ ÀÖ¾î ¿ìÀ§¸¦ Á¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÁÖ¿ä µ¿¹ÝÁø´Ü ½ÃÀå ÁøÃâ ±â¾÷À¸·Î´Â Abbott Molecular Inc., Thermo Fisher Scientific Inc., Dako Inc., Qiagen Ltd. µîÀÌ ÀÖÀ¸¸ç, À̵éÀº µ¿¹ÝÁø´Ü °³¹ß¿¡ ÀÖ¾î ¶Ñ·ÇÇÑ ±â¼ú·Â°ú Àü¹®¼ºÀ» º¸À¯Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Thermo Fisher ScientificÀº ºÐÀÚÁø´Ü Àü¹®°¡·Î ¾Ë·ÁÁ® ÀÖÀ¸¸ç, ÀÌ ºÐ¾ß¿¡¼­ ´Ù¾çÇÑ Á¦Ç°À» Á¦°øÇϰí ÀÖ½À´Ï´Ù. µ¿¹ÝÁø´Ü ½ÃÀå¿¡¼­´Â FDA ½ÂÀÎ ¹× À¯·´ CE ¸¶Å©¿Í °°Àº ±ÔÁ¦ ¿ä°ÇÀ» ÁؼöÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ǰÁú Ç¥ÁØÀ» ¼º°øÀûÀ¸·Î ÁؼöÇÑ ½ÇÀûÀÌ ÀÖ´Â ±â¾÷ÀÌ ´õ À¯¸®ÇÑ À§Ä¡¸¦ Â÷ÁöÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå µ¿¹ÝÁø´Ü ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå µ¿¹ÝÁø´ÜÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå µ¿¹ÝÁø´Ü ¾÷°è Á¶»ç

Á¦5Àå µ¿¹ÝÁø´Ü ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå µ¿¹ÝÁø´Ü ½ÃÀå »óȲ

Á¦7Àå µ¿¹ÝÁø´Ü ½ÃÀå : Á¦Ç° À¯Çüº°

Á¦8Àå µ¿¹ÝÁø´Ü ½ÃÀå : ¿ëµµº°

Á¦9Àå µ¿¹ÝÁø´Ü ½ÃÀå : ±â¼úº°

Á¦10Àå µ¿¹ÝÁø´Ü ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå µ¿¹ÝÁø´Ü ½ÃÀå : Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® : µ¿¹ÝÁø´Ü ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Companion Diagnostics Market size was valued at USD 6,978.12 Million in 2023, expanding at a CAGR of 12.2% from 2024 to 2032.

A companion diagnostic is a medical instrument, frequently an in vitro diagnostic (IVD), that offers data necessary for the safe and efficient administration of a related medication or biological product. It identifies patients who are likely to be at increased risk for serious side effects due to the treatment with a particular therapeutic product. In addition, there is an increasing prevalence of carcinogenic diseases which increases the need for effective genomic testing, leading to global demand for companion diagnostics. However, high capital investment is necessary for the discovery, development and validation of biomarkers, which is hindering the growth of the market. Furthermore, companion diagnostics are increasingly used in drug development by healthcare providers which caused substantial growth in the market.

Companion Diagnostics Market- Market Dynamics

Growing Significance of Personalized Medicines

There is a growing awareness of personalized medicines as they allow for treatments that are tailored to the specific genetic makeup or characteristics of an individual patient. Companion diagnostics help identify biomarkers or genetic variations that can predict how a patient will respond to a particular treatment. This enables physicians to prescribe the most suitable medication for each patient based on their unique genetic profile. These tests empower healthcare providers to make informed clinical decisions and avoid the risk of unnecessary events. Therefore the growing significance of personalized medicines and companion diagnostics represents a paradigm shift in healthcare towards more precise, effective, and patient-centered approaches to treatment.

Companion Diagnostics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 12.2% over the forecast period (2024-2032)

Based on product type segmentation, the assay, kits & reagents segments dominated the market

Based on end user segmentation, the pharma and biotech segment dominates the market and is likely to maintain its dominance during the forecast period

Based on region, North America was the leading revenue generator in 2023

Companion Diagnostics Market- Segmentation Analysis:

The Global Companion Diagnostics Market is segmented based on Product Type, Technology, Application, End User, and Region.

The market is divided into two categories based on product type: assay, kits & reagents and software & services. The assay, kits & reagents segments dominated the market due to the availability of a wide variety of products and the growing usage of assays and in the healthcare sector.

The market is divided into three categories based on end users: pharma & biotech companies, clinical research organizations and reference laboratories. The pharma and biotech segment dominates the market and is likely to maintain its dominance during the forecast period. The rising adoption of companion diagnostics is due to the increasing significance of drug development in the healthcare industry.

Companion Diagnostics Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

The market for companion diagnostics is dominated by North America. The presence of numerous prominent companion diagnostics vendors and open clinical research facilities, the easy accessibility of technologically advanced devices and tools, and the significantly changed medical services infrastructure in the US and Canada are all factors contributing to the growth of the friend diagnostics market in North America. Furthermore, Asia-Pacific offers lucrative opportunities for market participants because of the region's high population base, growing awareness of companion diagnostics, improved medical care infrastructure, and growing demand for cutting-edge therapies. For instance, in November 2023, the FDA approved the FoundationOne CDx for use as a companion diagnostic to identify patients with advanced hormone receptor-positive, advanced breast cancer who are eligible for treatment.

Companion Diagnostics Market- Competitive Landscape:

Companies with a strong international presence and distribution network have an advantage in reaching healthcare providers and patients globally. The key market players in companion diagnostics include Abbott Molecular Inc., Thermo Fisher Scientific Inc., Dako Inc., Qiagen Ltd, etc. have distinct technological capabilities and expertise in companion diagnostics development. For instance, Thermo Fisher Scientific is known for its expertise in molecular diagnostics and has a wide range of offerings in this area. while Abbott Molecular Inc. has a strong portfolio of molecular assays. Compliance with regulatory requirements, such as FDA approvals and CE marking in Europe, is crucial in the companion diagnostics market. Companies with a track record of successful regulatory approvals and adherence to quality standards may have a stronger position.

Recent Developments:

In November 2023, Foundation Medicine Inc. an American molecular insight company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOneCDx to be used as a companion diagnostic for AstraZeneca's Truqap.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL COMPANION DIAGNOSTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

ARUP Laboratories

Roche Molecular Systems Inc.

Dako Inc.

Qiagen Ltd.

bioMerieux Inc.

Ventana Medical Systems Inc.

Abbott Molecular Inc.

Myriad Genetics Inc.

Biogenex Laboratories, Inc.

Thermo Fisher Scientific Inc.

Leica Biosystems Nussloch GmbH

Others

GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL COMPANION DIAGNOSTICS MARKET, BY APPLICATION - MARKET ANALYSIS, 2019 - 2032

GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032

GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL COMPANION DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1.Companion Diagnostics Market Overview

2.Executive Summary

3.Companion Diagnostics Key Market Trends

4.Companion Diagnostics Industry Study

5.Companion Diagnostics Market: COVID-19 Impact Analysis

6.Companion Diagnostics Market Landscape

7.Companion Diagnostics Market - By Product Type

8.Companion Diagnostics Market - By Application

9.Companion Diagnostics Market - By Technology

10.Companion Diagnostics Market - By End User

11.Companion Diagnostics Market- By Geography

12.Key Vendor Analysis- Companion Diagnostics Industry

13.360 Degree Analyst View

14.Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â